Clinical Trials Using Autologous NKG2D CAR-expressing T-lymphocytes CM-CS1

Clinical trials are research studies that involve people. The clinical trials on this list are studying Autologous NKG2D CAR-expressing T-lymphocytes CM-CS1. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

    This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r / r AML / MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r / r AML / MDS patients.
    Location: 4 locations

  • A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

    THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU / US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).
    Location: 2 locations